| Title |
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
|
|---|---|
| Published in |
Lung Cancer: Targets and Therapy, October 2011
|
| DOI | 10.2147/lctt.s16440 |
| Pubmed ID | |
| Authors |
Masayuki Takeda, Isamu Okamoto, Yasumasa Nishimura, Kazuhiko Nakagawa |
| Abstract |
The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been developed. Such monoclonal antibodies have shown efficacy in combination with chemotherapy and radiotherapy. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, and its effects in combination with radiation have been sufficiently promising to warrant further investigation in several types of cancer. Furthermore, the typical severe dermatologic toxicities associated with other monoclonal antibodies to EGFR have not been observed with nimotuzumab. We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 26% |
| Researcher | 6 | 19% |
| Other | 4 | 13% |
| Professor > Associate Professor | 4 | 13% |
| Student > Ph. D. Student | 3 | 10% |
| Other | 1 | 3% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Chemistry | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Other | 7 | 23% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2016.
All research outputs
#8,533,995
of 25,371,288 outputs
Outputs from Lung Cancer: Targets and Therapy
#43
of 128 outputs
Outputs of similar age
#49,865
of 143,950 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#1
of 1 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 128 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,950 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them